SCHEMBL334997

SCHEMBL334997

Cc1cccc(C(NC(=O)c2ccc(C(C)C)cc2)C(O)C(=O)Nc2ccc3nc(N)sc3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.46
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
LCK P06239 1/20 0.43
EPHX2 P34913 4/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 1/20 0.43
SCN4A P35499 1/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
KMT2A Q03164 1/20 0.39
EIF2S1 P05198 1/20 0.38
EIF2AK3 Q9NZJ5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335590 0.91 NPC1 (0.50) KITNPC1RAB9ASMN1; SMN2EPHX2
SCHEMBL336521 0.88 NPC1 (0.45) KITNPC1RAB9ASMN1; SMN2LCK
SCHEMBL336282 0.87 KIT (0.46) KITNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL335893 0.86 KIT (0.49) KITNPC1RAB9ASMN1; SMN2LCK
SCHEMBL335307 0.85 SMN1; SMN2 (0.47) KITNPC1RAB9ASMN1; SMN2LCK
SCHEMBL336153 0.84 EPHX2 (0.47) KITNPC1RAB9ASMN1; SMN2LCK
SCHEMBL335874 0.83 MAPT (0.39) RAB9ASMN1; SMN2LMNAMAPTHTT
SCHEMBL8218636 0.83 NPC1 (0.46) KITNPC1RAB9ASMN1; SMN2LCK
SCHEMBL335863 0.81 F9 (0.51) EIF2S1EIF2AK3
SCHEMBL335151 0.79 NPC1 (0.48) KITNPC1RAB9ASMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
EP-2069289-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS Sanofi-Aventis (FR) 2009-06-17 EP claimed
WO-2008031509-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI-AVENTIS (FR) 2008-03-20 WO claimed
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 KIT 3674/4885NPC1 2621/4885RAB9A 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.